Evidence map›Paper›PMID 38198045›Full record

ArticleMolecular neurobiology2024

Wnt3a/GSK3β/β-catenin Signalling Modulates Doxorubicin-associated Memory Deficits in Breast Cancer.

Wen Li, Chen Gan, Sheng Yu, Jian Xu, LingXue Tang, Huaidong Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Cognitive dysfunction in chemobrain: Molecular mechanisms and therapeutic implications.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wen Li *Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, 230601, China.ORCID http://orcid.org/0000-0002-4936-8143
Chen Gan *Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, 230601, China.
Sheng Yu *Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, 230601, China.
Jian XuDepartment of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, 230601, China.
LingXue TangDepartment of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, 230601, China.
Huaidong ChengThe Third School of Clinical Medicine, Southern Medical University, Guangzhou, 510500, China. chd1975ay@126.com.
Anhui Medical University · CNThird Affiliated Hospital of Southern Medical University · CN

Funding

National Natural Science Foundation of China 81872504
6 · The paper itself

Abstract

backgroundChemobrain is widespread in breast cancer patients receiving chemotherapy. However, the exact mechanism, especially the associated signalling pathway, is not currently clear. This study was to evaluate the behavioural changes in breast cancer mice after chemotherapy and to further explore the role of Wnt3a/glycogen synthase kinase (GSK3β)/β-catenin signalling in chemobrain.

methodsMMTV-PyMT(+) breast cancer mice were injected intraperitoneally with doxorubicin (4 mg/kg) once a week for three weeks to establish a chemobrain model. The Morris water maze (MWM) and novel object recognition (NOR) tests were performed to assess the learning and memory ability. Electron microscopy was used to observe the structural changes in the hippocampal CA1 region. The brain tissue of breast cancer mice after chemotherapy was taken out for mRNA-seq detection. Then, the expression levels and phosphorylation of key proteins in the Wnt3a/GSK3 β/β-catenin signalling pathway were evaluated through Western blotting (WB) and immunofluorescence.

resultsDoxorubicin-induced spatial and short-term memory impairment was observed in breast cancer mice, and obvious neuronal damage could be seen in the hippocampal CA1 region. Immunofluorescence staining for GSK3β was increased. Wnt signalling pathway is highly enriched from mRNA-seq analysis, with GSK3β genes at important nodes. The relative protein levels of p-PI3K, p-AKT, p-GSK3 β, Wnt3a and TCF-1 were decreased significantly, while the p-β-catenin level was increased. After injection of the GSK3β inhibitor sb216763 (1 ng/0.5 µl/side), hippocampal neuronal injury was alleviated to some extent, and the changes in the expression of proteins upstream and downstream of this signalling pathway were reversed.

conclusionWnt3a/GSK3 β/β-catenin signalling is likely involved in doxorubicin-induced memory impairment. This result provides basic evidence for the further study of chemobrain in breast cancer.

Indexed as

beta CateninBreast NeoplasmsDoxorubicinGlycogen Synthase Kinase 3 betaMemory DisordersWnt3A ProteinAnimalsFemaleMiceSignal TransductionWnt Signaling Pathwaybeta CateninDoxorubicinGlycogen Synthase Kinase 3 betaWnt3A ProteinWnt3a protein, mouseBreast CancerChemobrainDoxorubicinHippocampusMemory ImpairmentWnt3a/GSK3 β/β-catenin Signalling

Identifiers

PMID38198045
OpenAlexW4390701359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.